Large gap with delayed quotes
|
Last quote
03/02/2026
-
10:42:47
|
Bid
03/02/2026 -
11:05:11
|
Bid Volume |
Ask
03/02/2026 -
11:12:14
|
Ask Volume |
|---|---|---|---|---|
|
114.00
+0.20
(
+0.18% )
|
113.60
|
160 |
114.40
|
424 |
Analysis date: 27.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 27.02.2026.
Interest
Weak
Weak
Two stars since 27.02.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 19.12.2025 at a price of 100.60.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 05.12.2025.
4wk Rel Perf
-7.43%
-7.43%
The four-week dividend-adjusted underperformance versus STOXX600 is 7.43%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 07.11.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.25%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.83%.
Mkt Cap in $bn
2.48
2.48
With a market capitalization between $2 & $8bn, COSMO PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
24.62
24.62
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
67.59
67.59
The estimated PE is for the year 2027.
LT Growth
1662.29%
1662.29%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
1.66%
1.66%
The earnings forecasts are not sufficient to cover the twelve month estimated dividend.
Beta
117
117
For 1% of index variation, the stock varies on average by 1.17%.
Correlation
0.28
0.28
Stock movements are strongly independent of index variations.
Value at Risk
53.26
53.26
The value at risk is estimated at CHF 53.26. The risk is therefore 46.81%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
10.11.2017
10.11.2017